China
Africa
Explore chapters and articles related to this topic
Complementary and Alternative Medicine in Older Adults
Published in K. Rao Poduri, Geriatric Rehabilitation, 2017
In 2007, a randomized multicenter clinical trial of over 900 BPH patients was conducted from September 2002 to December 2003 across seven therapeutic drug groups, including selective adrenoceptor antagonist (terazosin, doxazosin, tamsulosin, naftopidil), 5-alpha-reductase inhibitor (finasteride, epristeride), and natural product (cernilton, prepared from Secale cereale [rye] pollen). According to baseline, at average follow-up of 6 months, no difference in the International Prostate Symptom Score was noted across the therapeutic intervention groups. However, prostatic volume and transitional zone volume were significantly decreased in the 5-alpha-reductase inhibitor group, and more significant symptomatic improvements were noted in the cernilton, doxazosin, and naftopidil groups.190
A multicenter retrospective study on evaluation of predicative factors for positive biopsy of prostate cancer in real-world setting
Published in Current Medical Research and Opinion, 2021
Ben Xu, Gonghui Li, Chuize Kong, Ming Chen, Bin Hu, Qing Jiang, Ningchen Li, Liqun Zhou
In this retrospective, multicenter, real-world observational study conducted in seven centers in China in the real-world setting, patients who were receiving prostate biopsy for the first time in third grade and Class A hospitals nationwide between July 01, 2012 and June 30, 2017 were retrospectively included. The study was approved by the institutional ethical committee of Peking University First Hospital and also by the ethics committee of all the participating centers (IRBK-2019-006-01): Sir Run Run Shaw Hospital, Zhejiang University School of Medicine; First hospital of China Medical University; Affiliated Zhongda Hospital of Southeast University; Liaoning Cancer Hospital and Institute, Cancer Hospital of China Medical University; The Second Affiliated Hospital of Chongqing Medical University and Peking University Shougang Hospital (2019ZDSYLL040-P01). Male patients of all ages with total PSA (tPSA) >4 ng/mL within 30 days prior to biopsy and undergoing biopsy for the first time were included. Patients were excluded if they have used androgen deprivation therapy (Leuprorelin, Triptorelin and Goserelin) or 5a reductase inhibitor (Dutasteride, Finasteride and Epristeride) within three months prior to biopsy, diagnosed with urinary tract infection within two weeks prior to biopsy or undergone catheterization, received prostate biopsy previously in other hospital, or with tPSA ≤ 4 ng/mL within 30 days prior to biopsy.
The hop-derived compounds xanthohumol, isoxanthohumol and 8-prenylnaringenin are tight-binding inhibitors of human aldo-keto reductases 1B1 and 1B10
Published in Journal of Enzyme Inhibition and Medicinal Chemistry, 2018
Jan Moritz Seliger, Livia Misuri, Edmund Maser, Jan Hintzpeter
Interestingly, the abovementioned substances show an uncompetitive mode of action with respect to both, the substrate and the co-factor binding site. Hypothetically speaking, this would mean that the inhibitor does not bind to the enzyme–NADPH binary complex as expected, but, instead, to the subsequent and transient enzyme conformation after the product release but before the release of NADP+. This mechanism was previously hypothesised by Harris and Kozarich, 199778 and Copeland 200579 for the binding of epristeride to the NADPH-dependent steroid-5α reductase (M. mulatta).
Recent advances in the understanding of urothelial tumorigenesis
Published in Expert Review of Anticancer Therapy, 2023
Masato Yasui, Liam Cui, Hiroshi Miyamoto
More recently, we assessed the effects of 5α-reductase inhibitors, which could block conversion of testosterone to the more potent androgen dihydrotestosterone, on urothelial tumorigenesis [25]. Three 5α-reductase inhibitors clinically used, dutasteride, finasteride, and epristeride, at their supra-pharmacological doses failed to considerably prevent the carcinogen-mediated malignant transformation of SVHUC cells, suggesting that testosterone itself is an active form of androgen in urothelial cells.